Host: Jennifer Caudle, DO

Guest: Elaine Edmonds, MD

Guest: Mary Kay Fink, APN

Guest: Donald Negroski, MD

Guest: Timothy West, MD

Below please see Important Safety Information, including boxed WARNING, and Prescribing Information and Medication Guide at www.mavenclad.com.

Nearly one million individuals are afflicted with multiple sclerosis (MS) in the U.S. alone, with relapsing forms of MS being the most common.

Dr. Jennifer Caudle welcomes Dr. Timothy West, Dr. Donald Negroski, Mary Kay Fink and Dr. Elaine Edmonds to discuss treating patients with MAVENCLAD® (cladribine) tablets, the only treatment that can deliver proven efficacy in relapsing-remitting and active secondary progressive MS with a unique dosing schedule of up to 20 days of oral treatment over two years. The MS experts will walk through key clinical efficacy and safety data for MAVENCLAD, as well as provide their own perspectives on how the treatment fits into the current MS landscape and what patient types are best suited for treatment with MAVENCLAD.

MAVENCLAD has a boxed WARNING for malignancies and risk of teratogenicity. Do not take MAVENCLAD if you have a current malignancy, are pregnant or plan to become pregnant, have HIV or active chronic infection, have a hypersensitivity to cladribine or breastfeed during or for at least 10 days after the last dose. Follow recommended screening and monitoring prior ...